mundipharma_4_204_of_291

Mundipharma names new President and CEO

pharmafile | December 13, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Mundipharma, Napp, Napp Pharmaceuticals, appointment 

Shortly following its announcement of Philippe Mazas as Chief Information Officer, Mundipharma has revealed it has appointed Alberto Martinez as its new President and Chief Executive Officer.

Martinez takes over the reins at the company from predecessor Anthony Mattessich who held the role for 12 years, and has himself worked with Mundipharma for 14 years since joining in Spain in 2003. Over time, he transitioned to become General Manager of Mundipharma’s Spanish business, where he led a corporate turnaround between 2008 and 2014. In 2014, Martinez was appointed Managing Director of Napp Pharmaceuticals in the UK, against driving a robust transformation programme with the company. Most recently, Martinez held the role of Regional Director of Northern Europe at Mundipharma before being appointed in October 2016 as European Director of Commercial Operations.

The company said on release of the news: “With his proven strategic, financial and operational capabilities together with his strong commitment to commercialization and growth, the Board of Directors is confident Alberto will enhance value for business partners, employees and patients alike.”

According to the company, Martinez’s remit will focus on “expanding and diversifying the network’s product portfolio, where the network is open to new alliance opportunities at all stages of asset maturity across the commercial platforms of specialist-driven primary care, specialty care (including emergency care, oncology and biosimilars) and established brands”. Based at the Mundipharma network campus in Cambridge, Martinez will also “oversee European business development, HR and finance functions.  Additionally, the functions of research and development, global manufacturing and supply chain and IT will also fall under Alberto’s new remit.”

“I feel honoured and privileged to be given the opportunity to lead the Mundipharma organisations in Europe in the next chapter of our evolution and success,” Martinez commented. “I am committed to ensure that we remain ambitious and agile so we continue to bring valuable and innovative medicines to patients and healthcare providers as a successful, diversified and forward-thinking organisation.”

Related Content

european_commission_web

Europe extends Invokana indication to cover diabetic kidney disease in type 2 diabetes patients

European Commission has moved to expand the existing approved indication for Mundipharma’s Invokana (canagliflozin), making …

sarah_mcdonald

Myeloma UK reveals new Director of Research appointment

UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, …

white_and_ford

Abbott CEO to step down after 21 years

After more than two decades at the head of the company, it has emerged that …

Latest content